We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunicum - ilixadencel in MERECA Phase II - results soon !
IMMU.ST 10.06-1.1%4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: loparn9/25/2019 11:25:23 AM
  Read Replies (1) of 17
Immunicum CEO presented the MERECA results in a video today. There you can see explicit survival data for all 58 + 30 patients among other data.

I think this could pave the way for a deal with Big Pharma later on.

I have through these new data estimated/guessed a forecast for the future median overall survival that could be around 30-37 months in the ilixadencel group and around 23 months in the control group.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext